DE60303961T2 - Modifizierte saccharide, deren konjugate sowie deren herstellung - Google Patents

Modifizierte saccharide, deren konjugate sowie deren herstellung Download PDF

Info

Publication number
DE60303961T2
DE60303961T2 DE60303961T DE60303961T DE60303961T2 DE 60303961 T2 DE60303961 T2 DE 60303961T2 DE 60303961 T DE60303961 T DE 60303961T DE 60303961 T DE60303961 T DE 60303961T DE 60303961 T2 DE60303961 T2 DE 60303961T2
Authority
DE
Germany
Prior art keywords
saccharide
formula
alkyl
modified
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303961T
Other languages
German (de)
English (en)
Other versions
DE60303961D1 (de
Inventor
Aldo Giannozzi
Giovanni Averani
Francesco Norelli
Paolo Costantino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Application granted granted Critical
Publication of DE60303961D1 publication Critical patent/DE60303961D1/de
Publication of DE60303961T2 publication Critical patent/DE60303961T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60303961T 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung Expired - Lifetime DE60303961T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220198 2002-08-30
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (2)

Publication Number Publication Date
DE60303961D1 DE60303961D1 (de) 2006-05-04
DE60303961T2 true DE60303961T2 (de) 2006-10-26

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303961T Expired - Lifetime DE60303961T2 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung

Country Status (16)

Country Link
US (2) US8895516B2 (OSRAM)
EP (1) EP1534342B1 (OSRAM)
JP (2) JP5268222B2 (OSRAM)
CN (2) CN101863998B (OSRAM)
AT (1) ATE319481T1 (OSRAM)
AU (1) AU2003260921B2 (OSRAM)
BR (1) BR0314089A (OSRAM)
CA (1) CA2497167C (OSRAM)
DE (1) DE60303961T2 (OSRAM)
DK (1) DK1534342T3 (OSRAM)
ES (1) ES2260682T3 (OSRAM)
GB (1) GB0220198D0 (OSRAM)
MX (1) MXPA05002315A (OSRAM)
NZ (1) NZ538703A (OSRAM)
RU (2) RU2005108992A (OSRAM)
WO (1) WO2004019992A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
JP4827726B2 (ja) * 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US8062641B2 (en) * 2005-05-06 2011-11-22 Novartis Ag Immunogens for meningitidis-A vaccines
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BR112012010223A2 (pt) * 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
DK2608805T4 (da) 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
KR102428253B1 (ko) * 2016-03-15 2022-08-02 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 신규한 다당류-단백질 접합체 및 이의 제조방법
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US11090374B2 (en) * 2017-02-24 2021-08-17 Merck Sharp & Dohme Corp. Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3934696A1 (en) * 2019-03-08 2022-01-12 GlaxoSmithKline Biologicals S.A. Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司(Us) 脑膜炎奈瑟氏菌组合物及其方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
ES2067854T3 (es) * 1990-03-15 1995-04-01 Tanabe Seiyaku Co Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo.
WO1995018144A1 (en) * 1993-12-28 1995-07-06 Pfizer Inc. Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
KR100593466B1 (ko) * 1997-01-21 2007-04-25 파스퇴르 메리오 세룸 에 박신 다당류-펩타이드접합체
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
DE69737298T2 (de) * 1997-08-08 2007-06-28 Dade Behring Marburg Gmbh Konjugate von polysacchariden und biomolekülen
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2318117T3 (es) 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
US20150166593A1 (en) 2015-06-18
CN101863998A (zh) 2010-10-20
MXPA05002315A (es) 2005-06-08
RU2008150551A (ru) 2010-06-27
JP5314745B2 (ja) 2013-10-16
EP1534342A1 (en) 2005-06-01
AU2003260921B2 (en) 2008-03-06
CA2497167A1 (en) 2004-03-11
CA2497167C (en) 2011-07-12
DK1534342T3 (da) 2006-07-10
GB0220198D0 (en) 2002-10-09
RU2531909C2 (ru) 2014-10-27
CN1688343B (zh) 2010-09-08
CN1688343A (zh) 2005-10-26
AU2003260921A1 (en) 2004-03-19
JP2006511465A (ja) 2006-04-06
EP1534342B1 (en) 2006-03-08
BR0314089A (pt) 2005-11-16
NZ538703A (en) 2006-09-29
JP2012017342A (ja) 2012-01-26
RU2005108992A (ru) 2005-11-10
JP5268222B2 (ja) 2013-08-21
WO2004019992A1 (en) 2004-03-11
DE60303961D1 (de) 2006-05-04
US8895516B2 (en) 2014-11-25
ATE319481T1 (de) 2006-03-15
ES2260682T3 (es) 2006-11-01
CN101863998B (zh) 2012-08-29
US20060263390A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
DE60303961T2 (de) Modifizierte saccharide, deren konjugate sowie deren herstellung
EP1777236B1 (en) Modified saccharides having improved stability in water for use as a medicament
DE60314756T2 (de) Membranvesikel (omv) mit verbesserten eigenschaften
EP2216044B1 (en) Capsular polysaccharide solubilisation and combination vaccines
EP1506007B1 (en) Mucosal combination vaccines for bacterial meningitis
CN100491403C (zh) 具有改善的水中稳定性的修饰的糖类
AU2003216633B2 (en) Modified saccharides having improved stability in water
AU2014218428A1 (en) Capsular polysaccharide solubilisation and combination vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIEN, IT